Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom pope who wrote (12142)	6/23/2004 10:21:29 AM
From: Biomaven	Read Replies (1) of 52153

Been really busy at work, so not much time for biotech alas. But I thought I'd comment on the KOSN debacle. The real issue here is not the problem with their trial - these things happen in oncology drugs and are the reason you can't put too many biotech eggs into any one basket. The big issue is the price movement before the announcement. Certainly a lot of people knew about this before us. It may not have been a leak from KOSN itself - instead it could be a leak from a doctor engaged in the trial, or from partner Roche. I would encourage shareholders to ask the SEC to investigate the trading before the news (enforcement@sec.gov is the email address I believe). From a trading perspective it was hard to disentangle the early decline from the general post-ASCO malaise given that KOSN didn't report anything exciting at ASCO. I still have a moderate position (this is one that I had trimmed some over the last few months). Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next